Cibc World Market Inc. Buys 11,536 Shares of Natera, Inc. (NASDAQ:NTRA)

by · The Markets Daily

https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?w=250&h=150&zc=2&src=https://www.marketbeat.com/logos/natera-inc-logo.jpg?v=20221117161649
Cibc World Market Inc. increased its position in shares of Natera, Inc. (NASDAQ:NTRA – Free Report) by 187.9% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 17,676 shares of the medical research company’s stock after acquiring an additional 11,536 shares during the quarter. Cibc World Market Inc.’s holdings in Natera were worth $860,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Credit Suisse AG boosted its stake in shares of Natera by 1.2% in the 2nd quarter. Credit Suisse AG now owns 1,208,687 shares of the medical research company’s stock valued at $58,815,000 after purchasing an additional 14,302 shares during the last quarter. B. Metzler seel. Sohn & Co. AG raised its position in shares of Natera by 116.5% during the second quarter. B. Metzler seel. Sohn & Co. AG now owns 21,552 shares of the medical research company’s stock worth $1,049,000 after purchasing an additional 11,599 shares during the period. State Board of Administration of Florida Retirement System lifted its holdings in shares of Natera by 1.5% during the 2nd quarter. State Board of Administration of Florida Retirement System now owns 101,913 shares of the medical research company’s stock valued at $4,959,000 after purchasing an additional 1,542 shares in the last quarter. Hsbc Holdings PLC boosted its holdings in shares of Natera by 207.3% in the second quarter. Hsbc Holdings PLC now owns 50,717 shares of the medical research company’s stock valued at $2,507,000 after buying an additional 34,212 shares during the period. Finally, Franklin Resources Inc. increased its position in shares of Natera by 3,740.8% during the second quarter. Franklin Resources Inc. now owns 164,961 shares of the medical research company’s stock worth $8,027,000 after acquiring an additional 160,666 shares in the last quarter. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

NTRA has been the topic of several research reports. The Goldman Sachs Group cut their target price on Natera from $60.00 to $52.00 and set a “buy” rating on the stock in a research note on Friday, October 20th. Sanford C. Bernstein started coverage on shares of Natera in a research note on Thursday, September 28th. They issued a “market perform” rating and a $48.00 price target for the company. Morgan Stanley reduced their target price on Natera from $70.00 to $68.00 and set an “overweight” rating for the company in a research note on Friday, November 10th. UBS Group reduced their target price on shares of Natera from $76.00 to $70.00 and set a “buy” rating for the company in a report on Thursday, November 9th. Finally, StockNews.com assumed coverage on Natera in a research report on Thursday, October 5th. They set a “sell” rating on the stock. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, five have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Natera presently has a consensus rating of “Moderate Buy” and an average price target of $64.00.

Read Our Latest Stock Report on NTRA

Insider Activity

In related news, CEO Steven Leonard Chapman sold 2,617 shares of the company’s stock in a transaction on Thursday, September 28th. The stock was sold at an average price of $45.82, for a total transaction of $119,910.94. Following the completion of the sale, the chief executive officer now directly owns 217,554 shares in the company, valued at approximately $9,968,324.28. The sale was disclosed in a filing with the SEC, which is available through this link. In other Natera news, insider Daniel Rabinowitz sold 732 shares of the business’s stock in a transaction on Thursday, September 28th. The shares were sold at an average price of $45.82, for a total transaction of $33,540.24. Following the sale, the insider now owns 179,110 shares of the company’s stock, valued at $8,206,820.20. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Steven Leonard Chapman sold 2,617 shares of the company’s stock in a transaction on Thursday, September 28th. The stock was sold at an average price of $45.82, for a total transaction of $119,910.94. Following the transaction, the chief executive officer now owns 217,554 shares of the company’s stock, valued at $9,968,324.28. The disclosure for this sale can be found here. In the last quarter, insiders have sold 22,155 shares of company stock worth $1,002,406. Insiders own 9.42% of the company’s stock.

Natera Stock Performance

NTRA opened at $58.28 on Wednesday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 4.23 and a current ratio of 4.37. Natera, Inc. has a 52-week low of $35.02 and a 52-week high of $63.00. The firm has a market cap of $7.01 billion, a P/E ratio of -12.89 and a beta of 1.33. The business’s fifty day moving average is $46.55 and its 200-day moving average is $49.39.

Natera (NASDAQ:NTRA – Get Free Report) last announced its quarterly earnings data on Wednesday, November 8th. The medical research company reported ($0.95) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.96) by $0.01. Natera had a negative net margin of 50.50% and a negative return on equity of 72.98%. The business had revenue of $268.30 million for the quarter, compared to analysts’ expectations of $259.27 million. During the same period last year, the firm posted ($1.25) earnings per share. The firm’s quarterly revenue was up 27.4% compared to the same quarter last year. Sell-side analysts expect that Natera, Inc. will post -3.92 EPS for the current fiscal year.

Natera Company Profile

(Free Report)

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

Further Reading

Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA – Free Report).